Trends in the intellectual property (IP) landscape of drug delivery systems

Starling-Windhof, Amanda; Srinivasan, Asur; Tomeo, Tina; Clark, Anne Marie; Mattei, Peter

doi:10.1016/b978-0-12-817778-5.00010-5

Cited by 3 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of marine natural products is typically connected with enormous financial investments to sustain experimentation costs (Giugni and Giugni, 2010), especially in the medical sector. Intellectual property, primarily in the form of patents, facilitates the commercialization potential (Starling-Windhof et al, 2020). The growing number of marine-based drugs that are entering clinical trials is paired by a cumulative increase in the number of published patents (Mandhare et al, 2019).…”

Section: Use Case Scenariosmentioning

confidence: 99%

The Essentials of Marine Biotechnology

Rotter

Barbier²,

Bertoni

et al. 2021

Front. Mar. Sci.

View full text Add to dashboard Cite

Coastal countries have traditionally relied on the existing marine resources (e.g., fishing, food, transport, recreation, and tourism) as well as tried to support new economic endeavors (ocean energy, desalination for water supply, and seabed mining). Modern societies and lifestyle resulted in an increased demand for dietary diversity, better health and well-being, new biomedicines, natural cosmeceuticals, environmental conservation, and sustainable energy sources. These societal needs stimulated the interest of researchers on the diverse and underexplored marine environments as promising and sustainable sources of biomolecules and biomass, and they are addressed by the emerging field of marine (blue) biotechnology. Blue biotechnology provides opportunities for a wide range of initiatives of commercial interest for the pharmaceutical, biomedical, cosmetic, nutraceutical, food, feed, agricultural, and related industries. This article synthesizes the essence, opportunities, responsibilities, and challenges encountered in marine biotechnology and outlines the attainment and valorization of directly derived or bio-inspired products from marine organisms. First, the concept of bioeconomy is introduced. Then, the diversity of marine bioresources including an overview of the most prominent marine organisms and their potential for biotechnological uses are described. This is followed by introducing methodologies for exploration of these resources and the main use case scenarios in energy, food and feed, agronomy, bioremediation and climate change, cosmeceuticals, bio-inspired materials, healthcare, and well-being sectors. The key aspects in the fields of legislation and funding are provided, with the emphasis on the importance of communication and stakeholder engagement at all levels of biotechnology development. Finally, vital overarching concepts, such as the quadruple helix and Responsible Research and Innovation principle are highlighted as important to follow within the marine biotechnology field. The authors of this review are collaborating under the European Commission-funded Cooperation in Science and Technology (COST) Action Ocean4Biotech – European transdisciplinary networking platform for marine biotechnology and focus the study on the European state of affairs.

show abstract

Section: Use Case Scenariosmentioning

confidence: 99%

The Essentials of Marine Biotechnology

Rotter

Barbier²,

Bertoni

et al. 2021

Front. Mar. Sci.

View full text Add to dashboard Cite

show abstract

“…PTX was the first cancer drug whose annual global sales reached $1 billion in 1997, and it achieved an all-time high annual turnover of $1.6 billion worldwide in 2001 . Although PTX has been used in clinics for decades now, research is still on the rise to develop improved delivery systems for this drug . The past decade (2009–2018) has seen a staggering 113 and 79% increases in the numbers of patents on oral and parenteral PTX delivery systems, respectively, relative to the prior decade (1999–2008), underscoring the still transformative nature of this field .…”

Section: Introductionmentioning

confidence: 99%

“…Although PTX has been used in clinics for decades now, research is still on the rise to develop improved delivery systems for this drug . The past decade (2009–2018) has seen a staggering 113 and 79% increases in the numbers of patents on oral and parenteral PTX delivery systems, respectively, relative to the prior decade (1999–2008), underscoring the still transformative nature of this field . Specifically, the number per decade of nanomaterial-based oral/parenteral PTX delivery patents has increased by >100% between 1998 and 2018 .…”

Section: Introductionmentioning

confidence: 99%

“…3 The past decade (2009−2018) has seen a staggering 113 and 79% increases in the numbers of patents on oral and parenteral PTX delivery systems, respectively, relative to the prior decade (1999−2008), underscoring the still transformative nature of this field. 3 Specifically, the number per decade of nanomaterial-based oral/parenteral PTX delivery patents has increased by >100% between 1998 and 2018. 3 Since its discovery in the 1960s, PTX has become an indispensable drug in the fight against cancer.…”

Section: Introductionmentioning

confidence: 99%

“…3 Specifically, the number per decade of nanomaterial-based oral/parenteral PTX delivery patents has increased by >100% between 1998 and 2018. 3 Since its discovery in the 1960s, PTX has become an indispensable drug in the fight against cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWO₄/Paclitaxel-Coloaded PEG-PLA Nanoparticles

et al. 2022

View full text Add to dashboard Cite

For many locally advanced tumors, the chemotherapy–radiotherapy (CT–RT) combination (“chemoradiation”) is currently the standard of care. Intratumoral (IT) CT-based chemoradiation has the potential to overcome the limitations of conventional systemic CT–RT (side effects). For maximizing the benefits of IT CT–RT, our laboratory has previously developed a radiation-controlled drug release formulation, in which anticancer drug paclitaxel (PTX) and radioluminescent CaWO4 (CWO) nanoparticles (NPs) are co-encapsulated with poly(ethylene glycol)–poly(lactic acid) (PEG-PLA) block copolymers (“PEG-PLA/CWO/PTX NPs”). These PEG-PLA/CWO/PTX NPs enable radiation-controlled release of PTX and are capable of producing sustained therapeutic effects lasting for at least one month following a single IT injection. The present article focuses on discussing our recent finding about the effect of the stereochemical structure of PTX on the efficacy of this PEG-PLA/CWO/PTX NP formulation. Stereochemical differences in two different PTX compounds (“PTX-S” from Samyang Biopharmaceuticals and “PTX-B” from Biotang) were characterized by 2D heteronuclear/homonuclear NMR, Raman spectroscopy, and circular dichroism measurements. The difference in PTX stereochemistry was found to significantly influence their water solubility (WS); PTX-S (WS ≈ 4.69 μg/mL) is about 19 times more water soluble than PTX-B (WS ≈ 0.25 μg/mL). The two PTX compounds showed similar cancer cell-killing performances in vitro when used as free drugs. However, the subtle stereochemical difference significantly influenced their X-ray-triggered release kinetics from the PEG-PLA/CWO/PTX NPs; the more water-soluble PTX-S was released faster than the less water-soluble PTX-B. This difference was manifested in the IT pharmacokinetics and eventually in the survival percentages of test animals (mice) treated with PEG-PLA/CWO/PTX NPs + X-rays in an in vivo human tumor xenograft study; at short times (<1 month), concurrent PEG-PLA/CWO/PTX-S NPs produced a greater tumor-suppression effect, whereas PEG-PLA/CWO/PTX-B NPs had a longer-lasting radio-sensitizing effect. This study demonstrates the importance of the stereochemistry of a drug in a therapy based on a controlled release formulation.

show abstract

Essentials of Marine Biotechnology

Kim¹

2019

View full text Add to dashboard Cite

Coastal countries have traditionally relied on the existing marine resources (e.g., fishing, food, transport, recreation, and tourism) as well as tried to support new economic endeavors (ocean energy, desalination for water supply, and seabed mining). Modern societies and lifestyle resulted in an increased demand for dietary diversity, better health and well-being, new biomedicines, natural cosmeceuticals, environmental conservation, and sustainable energy sources. These societal needs stimulated the interest of researchers on the diverse and underexplored marine environments as promising and sustainable sources of biomolecules and biomass, and they are addressed by the emerging field of marine (blue) biotechnology. Blue biotechnology provides opportunities for a wide range of initiatives of commercial interest for the pharmaceutical, biomedical, cosmetic, nutraceutical, food, feed, agricultural, and related industries. This article synthesizes the essence, opportunities, responsibilities, and challenges encountered in marine biotechnology and outlines the attainment and valorization of directly derived or bio-inspired products from marine organisms. First, the concept of bioeconomy is introduced. Then, the diversity of marine bioresources including an overview of the most prominent marine organisms and their potential for biotechnological uses are described. This is followed by introducing methodologies for exploration of these resources and the main use case scenarios in energy, food and feed, agronomy, bioremediation and climate change, cosmeceuticals, bio-inspired materials, healthcare, and well-being sectors. The key aspects in the fields of legislation and funding are provided, with the emphasis on the importance of communication and stakeholder engagement at all levels of biotechnology development. Finally, vital overarching concepts, such as the quadruple helix and Responsible Research and Innovation principle are highlighted as important to follow within the marine biotechnology field. The authors of this review are collaborating under the European Commission-funded Cooperation in Science and Technology (COST) Action Ocean4Biotech -European transdisciplinary networking platform for marine biotechnology and focus the study on the European state of affairs.

show abstract

Trends in the intellectual property (IP) landscape of drug delivery systems

Cited by 3 publications

References 17 publications

The Essentials of Marine Biotechnology

The Essentials of Marine Biotechnology

Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWO₄/Paclitaxel-Coloaded PEG-PLA Nanoparticles

Essentials of Marine Biotechnology

Contact Info

Product

Resources

About

Trends in the intellectual property (IP) landscape of drug delivery systems

Cited by 3 publications

References 17 publications

The Essentials of Marine Biotechnology

The Essentials of Marine Biotechnology

Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWO4/Paclitaxel-Coloaded PEG-PLA Nanoparticles

Essentials of Marine Biotechnology

Contact Info

Product

Resources

About

Effect of Paclitaxel Stereochemistry on X-ray-Triggered Release of Paclitaxel from CaWO₄/Paclitaxel-Coloaded PEG-PLA Nanoparticles